Your browser doesn't support javascript.
loading
Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease.
Takahashi, Atsushi; Ohira, Hiromasa; Abe, Kazumichi; Zeniya, Mikio; Abe, Masanori; Arinaga-Hino, Teruko; Nakamoto, Nobuhiro; Takaki, Akinobu; Kang, Jong-Hon; Joshita, Satoru; Suzuki, Yoshiyuki; Koike, Kazuhiko; Inui, Ayano; Tanaka, Atsushi.
Afiliação
  • Takahashi A; Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
  • Ohira H; Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
  • Abe K; Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
  • Zeniya M; Akasaka Sanno Medical Center, Japan.
  • Abe M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan.
  • Arinaga-Hino T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan.
  • Nakamoto N; Department of Internal Medicine, Keio University School of Medicine, Japan.
  • Takaki A; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
  • Kang JH; Center for Gastroenterology, Teine Keijinkai Hospital, Japan.
  • Joshita S; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Japan.
  • Suzuki Y; Department of Hepatology, Toranomon Hospital, Japan.
  • Koike K; Department of Gastroenterology and Hepatology, The Third Hospital of Jikei University School of Medicine, Japan.
  • Inui A; Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohamashi Tobu Hospital, Japan.
  • Tanaka A; Department of Medicine, Teikyo University School of Medicine, Japan.
Intern Med ; 2024 Jul 04.
Article em En | MEDLINE | ID: mdl-38960681
ABSTRACT
Objective Metabolic-associated fatty liver disease (MAFLD) has only recently been proposed; therefore, the characteristics of patients with autoimmune hepatitis (AIH) and MAFLD remain unclear. This study evaluated the effect of MAFLD on AIH patients with AIH. Methods We reevaluated the Japanese Nationwide Survey of AIH in 2018, which involved a survey of patients diagnosed with AIH between 2014 and 2017. We categorized patients with AIH according to the presence or absence of MAFLD and compared the clinical characteristics between the two groups. Results A total of 427 patients (77 men and 350 women) were included in this study. The overall prevalence of MAFLD was 10.5%. Compared to AIH patients without MAFLD, AIH patients with MAFLD had the following characteristics at the time of the AIH diagnosis (1) a higher body mass index, (2) a higher prevalence of hypertension, (3) mild elevation of hepatobiliary enzymes and total bilirubin, and (4) histologically progressive fibrosis. However, the levels of hepatobiliary enzymes and total bilirubin after treatment were significantly higher in AIH patients with MAFLD than in those without MAFLD. Conclusions AIH patients with MAFLD had characteristics different from those of AIH patients without MAFLD. These findings could help increase our understanding of patients with AIH with MAFLD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article